Lymphoma & Plasma Cell Disorders
News
First CAR T-cell therapy for multiple myeloma: Abecma
“The results of this trial represent a true turning point in the treatment of this disease.”
From the Journals
Poor survival with COVID in patients who have had HSCT
Conference Coverage
Omidubicel improves on umbilical cord blood transplants
Feature
FDA scrutinizes cancer therapies granted accelerated approval
From the Journals
High-dose chemo no better than standard dose for B-cell lymphoma
From the Journals
Don’t delay: Cancer patients need both doses of COVID vaccine
For patients with cancer, immune response to the first dose of the Pfizer COVID-19 vaccine is reduced, and there is a need for a booster dose at...
From the Journals
New inhibitor shows promise in previously failed B-cell malignancies
Pirtobrutinib (formerly known as LOXO-305) is an oral-dose, highly selective, reversible inhibitor.
Clinical Insights
mCODE: Improving data sharing to enhance cancer care
From the Journals
‘Phenomenal’ results with CAR T cells in R/R multiple myeloma
Conference Coverage
Maribavir seen as superior to other antivirals for CMV clearance post transplant
Conference Coverage
Using engineered T cells reduced acute, chronic GVHD